Table 3.

Premenopausal and postmenopausal treatment effects on proliferation and estrogen exposure biomarkers

Treatment group	Endometrial				Mammary
	Avg thickness (mm)	Epithelial area (%)	Glandular area (%)	Lobular area (%)	PGR mRNA	Ki67 mRNA	pS2 mRNA
OC−	1.4 (1.2–1.5)	10.1 (9.2–11.1)	14.0 (12.6–15.5)	0.78 (0.63–0.97)	16.8 (14.0–20.0)	0.014 (0.011–0.018)	0.50 (0.38–0.67)
OC+	1.1 (1.0–1.3)*	8.6 (7.8–9.5)*	12.4 (11.2–13.8)	0.90 (0.72–1.13)	17.1 (14.2–20.8)	0.029 (0.023–0.038)*	0.58 (0.43–0.79)
Soy−	0.89 (0.78–1.0)	7.3 (6.5–8.2)	9.3 (8.1–10.5)	0.64 (0.49–0.84)	9.7 (7.7–12.1)	0.019 (0.014–0.026)	0.25 (0.17–0.35)
Soy+	0.83 (0.72–0.94)	6.9 (6.1–7.7)	8.7 (7.7–9.9)	0.56 (0.43–0.73)	8.1 (6.4–10.2)	0.011 (0.008–0.015)†	0.20 (0.14–0.29)
CEE+	2.7 (2.4–3.1)‡	16.1 (14.3–18.0)‡	28.4 (15.0–32.2)‡	1.64 (1.26–2.14)‡	62.2 (49.6–78.0)‡	0.041 (0.030–0.055)‡	3.16 (2.21–4.52)‡

NOTE: Values represent geometric means with 95% confidence intervals. Treatment group n values are the same as stated in Materials and Methods.

Abbreviation: PGR, progesterone receptor.

^*P < 0.01, versus OC− group.

^†P < 0.01, versus Soy− group.

^‡P < 0.0001, versus Soy− group.